Charles A. Rowland Jr., Director at Viking Therapeutics, Inc. (VKTX), sold 60,000 shares at $35.57 ($2.1M) on 2025-10-27, disclosed to the SEC on 2025-10-28.
Open-market sale of $2.1M VKTX by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| GBIO | BUY | 2022-09-20 | $83K | — | Filing → |
| GBIO | BUY | 2022-09-19 | $552K | — | Filing → |
| GBIO | BUY | 2022-09-15 | $225K | — | Filing → |